NCT06155279 2026-01-13
CHIMERA
Istituto Oncologico Veneto IRCCS
Phase 2 Active not recruiting
Clinical Trials
8 trialsNCT04914897 2025-10-02
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)
Sanofi
Phase 2 Terminated
NCT02399371 2025-06-11
Pembrolizumab in Treating Patients With Malignant Mesothelioma
University of Chicago
Phase 2 Active not recruiting
NCT06318286 2025-05-25
PENINSULA
Hyogo Medical University
Phase 2 Recruiting
NCT04287829 2024-11-05
PEMMELA
The Netherlands Cancer Institute
Phase 2 Active not recruiting
NCT05425576 2024-03-15
OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition
Mateon Therapeutics
Phase 2 Not yet recruiting
NCT03654833 2023-03-14
MiST
University of Leicester
Phase 2 Unknown
NCT03175172 2019-04-04
Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM)
Aduro Biotech, Inc.
Phase 2 Terminated